IL-17AF Inhibitors & Biosimilars
1 drugsAbout IL-17AF
Interleukin-17AF (IL-17AF) is a pro-inflammatory cytokine heterodimer composed of IL-17A and IL-17F subunits, crucial for immune responses. As a key mediator in inflammatory pathways, it has emerged as a significant drug target in immunology.
IL-17AF is a compelling therapeutic target due to its involvement in driving inflammation. Currently, there is no genetic evidence data available linking IL-17AF to specific diseases.
IL-17AF is targeted by one FDA-approved biologic drug, BIMZELX (UCB INC), which has 5 indications in immunology. This first approval occurred in 2023.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Palmoplantar Pustulosis with only 1 trials.
- phase4 represents biological uncertainty with 50% completion.
Top Drugs
The competitive landscape is concentrated, with UCB INC holding the only approved drug.
High market concentration suggests high entry barriers or first-mover advantage for UCB INC.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-17AF, using biologic (other) modality.
Small molecule or alternative modalities represent a whitespace opportunity for differentiation.
Clinical Trials 58 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 9 | 1 | 3 | 90% |
| Phase 2 | 14 | 12 | 0 | 2 | 100% |
| Phase 3 | 25 | 16 | 0 | 9 | 100% |
| Phase 4 | 6 | 2 | 2 | 2 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2023 - 2023)
The first and only drug approval for IL-17AF was BIMZELX in 2023.
Recent entry suggests potential for rapid growth or risk of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 52 clinical trials targeting IL-17AF.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities